A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Inclusion Criteria: * Patients having histologically-proven solid tumors, who are either refractory to standard chemotherapy; * Patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate; * Creatinine clearance according to Cockcroft-Gault formula : Normal \> 80 mL/min, Mild 50-80 mL/min, Moderate 30-\<50 mL/min; * A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies; * Potassium, calcium, magnesium and phosphorus values within the normal range; * Body Mass Index (BMI) must be within the range of 18 and 30 Exclusion Criteria: * Patients having CNS metastases, must have a CT or MRI of the brain performed to rule out CNS metastases; * Patients with leptomeningeal disease metastases; * Radiotherapy \</- weeks prior to starting study drug; * Major surgery \</ 4 weeks prior to the start of study; * Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14 days prior to starting study drug; Other protocol-defined inclusion/exclusion criteria may apply